Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.564 EUR | +6.29% | +9.40% | +94.71% |
05-31 | Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial | MT |
05-31 | Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial | CI |
Sales 2024 * | 239M 22.71M 21.03M 31.25M | Sales 2025 * | 343M 32.53M 30.12M 44.76M | Capitalization | 3.23B 307M 284M 422M |
---|---|---|---|---|---|
Net income 2024 * | -735M -69.78M -64.6M -96.01M | Net income 2025 * | -712M -67.59M -62.58M -93M | EV / Sales 2024 * | 15.5 x |
Net Debt 2024 * | 474M 45M 41.66M 61.91M | Net Debt 2025 * | 733M 69.62M 64.46M 95.8M | EV / Sales 2025 * | 11.6 x |
P/E ratio 2024 * |
-4.44
x | P/E ratio 2025 * |
-5.27
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
1 week | +9.40% | ||
Current month | +9.40% | ||
1 month | +82.56% | ||
3 months | +66.33% | ||
6 months | +129.00% | ||
Current year | +94.71% |
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | 11-30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 18-05-28 | |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
Date | Price | Change |
---|---|---|
24-06-07 | 4.564 | +6.29% |
24-06-06 | 4.294 | -2.28% |
24-06-05 | 4.394 | -0.86% |
24-06-04 | 4.432 | -0.45% |
24-06-03 | 4.452 | +6.71% |
Delayed Quote Börse Stuttgart, June 07, 2024 at 04:31 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- HNSA Stock
- 24H Stock